In-vitro activity of cefpodoxime against 1834 isolates from domiciliary infections at 20 UK centres.
A total of 1834 non-copy, general practice or outpatient isolates were collected by 20 hospital laboratories within the British Isles, and identified and tested for susceptibility to nine antimicrobial agents available by oral administration at one centre. Against Enterobacteriaceae cefpodoxime was the most active beta-lactam agent tested, the MIC90s being: for Escherichia coli 1.0 mg/l, for Proteus mirabilis 1.0 mg/l, for Citrobacter spp. 2.0 mg/l, and for Enterobacter spp., Serratia spp., Morganella spp. and Klebsiella spp. 16-64 mg/l. Cefpodoxime also showed a certain amount of activity against staphylococci and high activity against streptococci, the MIC90s being for Staphylococcus aureus 2 mg/l, for coagulase negative staphylococci 8 mg/l, for Streptococcus pyogenes 0.015 mg/l, for Str. pneumoniae 0.06 mg/l and for Str. agalactiae 0.5 mg/l.
Holt
H A
HA
Department of Medical Microbiology, Southmead Hospital, Bristol, UK.
Bywater
M J
MJ
Reeves
D S
DS
D015296:Ceftizoxime / Q000031:analogs & derivatives* / Q000494:pharmacology; D004755:Enterobacteriaceae / Q000187:drug effects*; D005194:Family Practice; D006801:Humans; D008826:Microbial Sensitivity Tests; D006113:United Kingdom; D000097623:Cefpodoxime
D015296:Ceftizoxime; D000097623:Cefpodoxime